Update Breast Cancer 2022 Part 5 – Early Stage Breast Cancer

The treatment of patients with early stage breast cancer has changed in recent years due to the introduction of pembrolizumab, olaparib, and abemaciclib. These and other drugs with the same class of active ingredient are currently in trial for various indications. This review article summarizes the...

Descripción completa

Detalles Bibliográficos
Autores principales: Fehm, Tanja N., Welslau, Manfred, Müller, Volkmar, Lüftner, Diana, Schütz, Florian, Fasching, Peter A., Janni, Wolfgang, Thomssen, Christoph, Witzel, Isabell, Beierlein, Milena, Belleville, Erik, Untch, Michael, Thill, Marc, Tesch, Hans, Ditsch, Nina, Lux, Michael P., Aktas, Bahriye, Banys-Paluchowski, Maggie, Kolberg-Liedtke, Cornelia, Hartkopf, Andreas D., Wöckel, Achim, Kolberg, Hans-Christian, Harbeck, Nadia, Stickeler, Elmar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Georg Thieme Verlag KG 2023
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9998178/
https://www.ncbi.nlm.nih.gov/pubmed/36908285
http://dx.doi.org/10.1055/a-2018-9053
Descripción
Sumario:The treatment of patients with early stage breast cancer has changed in recent years due to the introduction of pembrolizumab, olaparib, and abemaciclib. These and other drugs with the same class of active ingredient are currently in trial for various indications. This review article summarizes the latest results that have either been presented at major conferences such as the ESMO 2022 or published recently in international journals. This includes reports on newly discovered breast cancer genes, atezolizumab in neoadjuvant therapy in HER2-positive patients, long-term data from the APHINITY study, and on how preoperative peritumoral application of local anesthetics can influence the prognosis. We also present solid data on dynamic Ki-67 from the ADAPT studies.

Ejemplares similares